TLDR:
- Katalysen Ventures AB, through Venture Targeter 3, acquired all material assets of German healthtech company Smart4Diagnostics.
- The acquisition adds an initial value of around 10 MSEK to Katalysen’s portfolio.
Katalysen Ventures AB, through its subsidiary VT3, successfully acquired all material assets of German healthtech company Smart4Diagnostics. The acquisition was made through the newly founded S4DX GmbH, adding an initial value of about 10 MSEK to Katalysen’s portfolio. Co-investors and co-developers from Sweden, the UK, and the US participated in the transaction, giving Katalysen a 10.4% equity stake in S4DX.
The transaction is seen as a significant step for Katalysen’s Venture Targeter framework, with CEO Peter Almberg expressing excitement about the potential of S4DX’s platform to revolutionize diagnostic decision-making processes. Further details about the acquisition and the Venture Targeter framework will be shared by Katalysen Ventures in the coming days.
